ctDNA Testing After Neoadjuvant Chemotherapy and Radical Cystectomy Predicts Recurrence Risk in Patients with MIBC By Ogkologos - May 21, 2026 266 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the TOMBOLA study Source RELATED ARTICLESMORE FROM AUTHOR Two novel bispecific antibodies in combination with chemotherapy show efficacy in neuroendocrine carcinomas Sacituzumab tirumotecan plus pembrolizumab significantly prolongs progression-free survival in advanced non-small cell lung cancer Adding Abiraterone to ADT and Docetaxel Improves Survival in Metastatic Prostate Cancer MOST POPULAR Treating the Whole Person: How Cancer Centers Are Addressing Social Needs July 18, 2024 Adding Pembrolizumab To Preoperative Radiotherapy and Surgery Improves DFS for Patients... December 2, 2024 FDA Approves Belumosudil to Treat Chronic Graft-Versus-Host Disease August 18, 2021 Perioperative Durvalumab Plus Neoadjuvant Chemotherapy Results in Greater EFS and pCR... November 6, 2023 Load more HOT NEWS FDA Grants Accelerated Approval to Naxitamab for High-Risk Neuroblastoma in Bone... Sheriff’s Sergeant Is Now Fighting Stage III Breast Cancer After Missing... Predictive Performance of DNA Methylation-based Test in Combination with HPV16/18 Genotyping... Teen Created App To Help His Non-Verbal Sister And Others Like...
